MedAssets Beats on Both Top and Bottom Lines
May 2nd 2013 5:09PM
Updated May 2nd 2013 5:12PM
MedAssets (NAS: MDAS) reported earnings on May 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), MedAssets beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share grew significantly. GAAP earnings per share increased.
Margins expanded across the board.
MedAssets logged revenue of $172.8 million. The 13 analysts polled by S&P Capital IQ expected to see revenue of $164.7 million on the same basis. GAAP reported sales were 15% higher than the prior-year quarter's $149.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.41. The 13 earnings estimates compiled by S&P Capital IQ forecast $0.30 per share. Non-GAAP EPS of $0.41 for Q1 were 71% higher than the prior-year quarter's $0.24 per share. GAAP EPS of $0.13 for Q1 were much higher than the prior-year quarter's $0.00 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 80.2%, 110 basis points better than the prior-year quarter. Operating margin was 18.5%, 650 basis points better than the prior-year quarter. Net margin was 4.5%, 470 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $171.0 million. On the bottom line, the average EPS estimate is $0.29.
Next year's average estimate for revenue is $679.7 million. The average EPS estimate is $1.29.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 61 members out of 73 rating the stock outperform, and 12 members rating it underperform. Among 26 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 22 give MedAssets a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MedAssets is outperform, with an average price target of $20.88.
Is MedAssets the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add MedAssets to My Watchlist.
The article MedAssets Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.